
Introduction: The purpose of this study was to investigate factors associated with Fear of Cancer Recurrence (FCR) among gastric cancer patients following surgery. Methods: From 2016 to July 2, 2025, manual searches, in addition to searches of PubMed, Web of Science, Embase, Wanfang, VIP, and CNKI, were conducted. Review Manager 5.4.1 software was used to conduct a meta-analysis after two reviewers independently screened studies, extracted data, and evaluated quality. Results: Fourteen studies (2,729 patients) and 31 influencing factors were included. Higher social support was associated with lower FCR (odds ratio (OR) = 0.93, 95% CI: 0.90-0.97, p = 0.003), while disease perception showed no significant association (OR = 0.97, 95% CI: 0.72-1.32, p = 0.85). Self-perceived burden was marginally associated with higher FCR (OR = 1.25, 95% CI: 0.99-1.57, p = 0.06). Discussion: Unlike prior studies that predominantly investigated FCR in other cancer populations, this analysis focused on postoperative gastric cancer patients. Social support was associated with lower FCR, suggesting that social support-based psychological interventions may be applicable to these patients; self-perceived burden was marginally associated with FCR, indicating its potential as an influencing factor. As all included studies were observational, these findings only reflect correlations and require validation in prospective cohort studies. Conclusion: Social support was associated with lower FCR among postoperative gastric cancer patients, and self-perceived burden marginally predicted higher FCR; no other factors yielded significant associations. Screening for these factors during postoperative follow-up may inform individualized psychological interventions, though further prospective studies are required.
Following publication of the article entitled “A Revolution in Healthcare: AI-powered Cancer Imaging” [1], certain phrases and expressions were identified that were unclear or inconsistent with established scientific terminology. To ensure the accuracy and clarity of the published record, these expressions have been corrected using appropriate terminology that more accurately conveys the intended scientific meaning. These corrections are limited to the wording and terminology of the affected passages and do not alter the data, results, scientific interpretations, or conclusions of the article. The specific corrections are provided below: Section 2.2.2, Paragraph 1 Original text: It can evaluate big information to identify at-risk groups, enabling focused screening and preventative treatments [23]. Corrected text: It can evaluate extensive data to identify at-risk groups, enabling focused screening and preventative treatments [23]. Table 3, Column 1, Row 4 Original text: Super vector Machine Corrected text: Support Vector Machine The original article has been updated accordingly. This Corrigendum is published to maintain transparency and accuracy of the scholarly record. The corrected version of the article is available online at: https://www.eurekaselect.com/article/142266 The authors regret these errors and apologise for any inconvenience they may have caused.
The rapid development of high-throughput sequencing has generated large volumes of cross-sectional cancer genomic data, providing an important basis for studying tumor evolution. Reconstructing cancer progression from these static observations, however, remains challenging because temporal information is not directly observed and because genomic and multi-omics measurements are affected by biological heterogeneity and technical noise. This review examines three linked components: cross-sectional cancer genomic data, mutational-signature-based cancer progression inference, and clonal-evolution-based cancer progression inference. We compare the biological assumptions, data requirements, inferential targets, sources of uncertainty, validation strategies, and clinical applicability of these approaches, and discuss how single-cell and spatial technologies can complement cross-sectional inference. Rather than treating inferred trajectories as direct observations of tumor history, we emphasize the conditions under which evolutionary information can be extracted from cross-sectional data and the limitations that remain. We further distinguish established methodological evidence from emerging clinical applications, with the aim of clarifying current capabilities and priorities for future inference of cancer progression.
Background/Introduction: Early detection of hematological malignancies improves therapeutic outcomes, and digital pathology aids this, thus supporting clinical decision-making. A few image- analysis tools exist, but most are available only on proprietary platforms or require computational programming expertise, limiting their widespread adoption in routine diagnostics. To address this gap, we developed a fully automated, Mathematical Morphology (MM)-based image-analysis framework in Python, an open-source platform, to identify Red Blood Cell (RBC) morphological alterations in Acute Lymphoblastic Leukemia (ALL). Methods: MM algorithms were used for segmentation, binary and grayscale operations (intensity levels range 0-255) to enhance structural characteristics following morphological operations (dilation, erosion, opening, closing) for feature extraction from RBC images in a quantitative manner. RBC images of peripheral blood of 10 ALL cases (542 RBCs) and 5 healthy individuals (104 RBCs) were analyzed. Four features-area, perimeter, convexity, and solidity-were computed, and group differences were assessed using two-tailed t-tests with significance at p < 0.05. Results: Leukemic RBCs exhibited significantly reduced areas and perimeter compared with normal controls (p < 0.05), indicating size reduction with subtle boundary changes. Convexity and solidity did not differ significantly between groups, suggesting preservation of overall shape integrity despite reductions in cell dimensions. Discussion: This study presents an MM-based Python platform that detects morphological differences in RBCs associated with ALL. By matching the performance of earlier MATLAB-based methods while eliminating proprietary barriers, the proposed framework offers a cost-effective, accessible, and scalable tool for digital pathology. Conclusion: The developed software demonstrated its utility in early screening, underscoring its relevance in preventive oncology and positioning it to advance point-of-care diagnostic capabilities.
Abstract: Cervical cancer, primarily caused by high-risk human papillomavirus (HPV) strains, remains a significant global health concern. Conventional treatments, such as chemotherapy, radiotherapy, and surgery, have notable limitations and side effects, prompting the search for safer alternatives. Plant-derived phytochemicals have shown promise as natural bioactive compounds in cervical cancer therapy. This review highlights an integrative approach that combines in silico modeling, in vitro assays, and in vivo animal studies to assess the anticancer potential of these compounds. In silico methods, including molecular docking and virtual screening, have been used to identify compounds that target HPV oncoproteins and related cellular pathways. In vitro studies have demonstrated that phytochemicals, such as apigenin, luteolin, berberine, curcumin, and epigallocatechin-3- gallate, inhibit cervical cancer cell growth, induce apoptosis, and modulate signaling pathways in a dose-dependent manner. In vivo xenograft models further validated the antitumor efficacy of these compounds. This combined strategy accelerates the development of natural product-based therapies, reduces costs, and enhances translational success. Future research should focus on improving in silico predictive accuracy, employing more physiologically relevant in vitro models, optimizing delivery systems, exploring synergistic combinations, and identifying candidates for clinical trials. Utilizing natural inhibitors can result in safer and more effective therapies to alleviate the global impact of cervical cancer.